ADITYA CHAKRABORTY

Dr. ADITYA CHAKRABORTY

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 September 2023 in Journal of Statistical Theory and Applications
Verified
Journal Article
Open access
PDF file
ACADITYA CHAKRABORTY
ADITYA CHAKRABORTY
CTChris P. Tsokos
Chris P. Tsokos
Pancreatic cancer is one of the deadliest carcinogenic diseases affecting people all over the world. The majority of patients are usually detected at Stage III or Stage IV, and the chances of survival are very low once detected at the late stages. This study focuses on building an efficient data-driven analytical predictive model based on the associated risk factors and identifying the most contributing factors influencing the survival times of patients diagnosed with pancreatic cancer using the XGBoost (eXtreme Gradient Boosting) algorithm. The grid-search mechanism was implemented to compute the optimum values of the hyper-parameters of the analytical model by minimizing the root mean square error (RMSE). The optimum hyperparameters of the final analytical model were selected by comparing the values with 243 competing models. To check the validity of the model, we compared the model’s performance with ten deep neural network models, grown sequentially with different activation functions and optimizers. We also constructed an ensemble model using Gradient Boosting Machine (GBM). The proposed XGBoost model outperformed all competing models we considered with regard to root mean square error (RMSE). After developing the model, the individual risk factors were ranked according to their individual contribution to the response predictions, which is extremely important for pancreatic research organizations to spend their resources on the risk factors causing/influencing the particular type of cancer. The three most influencing risk factors affecting the survival of pancreatic cancer patients were found to be the age of the patient, current BMI, and cigarette smoking years with contributing percentages of 35.5%, 24.3%, and 14.93%, respectively. The predictive model is approximately 96.42% accurate in predicting the survival times of the patients diagnosed with pancreatic cancer and performs excellently on test data. The analytical methodology of developing the model can be utilized for prediction purposes. It can be utilized to predict the time to death related to a specific type of cancer, given a set of numeric, and non-numeric features.

31 August 2023 in Health Science Reports
Verified
Journal Article
Open access
MKMohammad Ebrahimi Kalan
Mohammad Ebrahimi Kalan
RJRime Jebai
Rime Jebai
WLWei Li
Wei Li
PGPrem Gautam
Prem Gautam
SASeyedeh Yasaman Alemohammad
Seyedeh Yasaman Alemohammad
ZTZiyad Ben Taleb
Ziyad Ben Taleb
Background: Smoking and vaping are linked to lung inflammation and lowered immune response.Objective: Examine the prevalence of coronavirus disease 2019 (COVID‐19) cases, testing, symptoms, and vaccine uptake, and associations with tobacco product use.Methods: Data came from the 2021 National Health Interview Survey. The 2021 Sample Adult component included 29,482 participants with a response rate of 50.9%. We investigated COVID‐19‐related outcomes by tobacco product use status and reported national estimates. Multivariable regression models were performed accounting for demographics (e.g., age, sex, poverty level), serious psychological distress, disability, and chronic health conditions.Results: In our regression analyses, odds of self‐reported COVID‐19 infection were significantly lower for combustible tobacco product users (vs. nonusers; adjusted odds ratio [AOR = 0.73; 95% confidence interval [CI] = 0.62–0.85]). Combustible tobacco users also were less likely to report ever testing for COVID‐19 (AOR = 0.88; 95% CI = 0.79–0.98), ever testing positive for COVID‐19 (AOR = 0.66; 95% CI = 0.56–0.77), and ever receiving COVID‐19 vaccine (AOR = 0.58; 95% CI = 0.51–0.66) compared with their nonuser peers. Compared to nonusers, users of any type of tobacco who contracted COVID‐19 had higher odds of losing smell (AOR = 1.36; 95%CI = 1.04–1.77), which was more pronounced among exclusive e‐cigarette users. The odds of receiving vaccine were lower for all current exclusive tobacco product users compared to nonusers (AORs = 0.40 to 0.70).Conclusions: Continued monitoring of tobacco product use and its association with respiratory diseases such as COVID‐19 is crucial to inform public health policies and programs. In addition, efforts to promote vaccination, especially among tobacco product users, are warranted.

29 November 2024 in Epilepsy & Behavior
Verified
Journal Article
Closed access
MGMiranda Gehris
Miranda Gehris
AIAteeqa Ijaz
Ateeqa Ijaz
ACADITYA CHAKRABORTY
ADITYA CHAKRABORTY
RJrime Jebai
rime Jebai
WLWei Li
Wei Li
MKMohammad Ebrahimi Kalan
Mohammad Ebrahimi Kalan

Verified
Journal Article
Open access
PDF file
ACADITYA CHAKRABORTY
ADITYA CHAKRABORTY
Mohan Dev PantMohan Dev Pant
Mohan Dev Pant
Background: Pancreatic cancer is among the most lethal malignancies, with poor prognosis and limited survival despite treatment advances. Accurate survival modeling is critical for prognostication and clinical decision-making. This study had three primary aims: (1) to determine the best-fitting survival distribution among patients diagnosed and deceased from pancreatic cancer across stages and treatment types; (2) to construct and compare predictive risk classification models; and (3) to evaluate survival probabilities using parametric, semi-parametric, non-parametric, machine learning, and deep learning methods for Stage IV patients receiving both chemotherapy and radiation. Methods: Using data from the SEER database, parametric models (Generalized Extreme Value, Generalized Pareto, Log-Pearson 3), semi-parametric (Cox), and non-parametric (Kaplan–Meier) methods were compared with four machine learning models (gradient boosting, neural network, elastic net, and random forest). Survival probability heatmaps were constructed, and six classification models were developed for risk stratification. ROC curves, accuracy, and goodness-of-fit tests were used for model validation. Statistical tests included Kruskal–Wallis, pairwise Wilcoxon, and chi-square. Results: Generalized Extreme Value (GEV) was found to be the best-fitting distribution in most of the scenarios. Stage-specific survival differences were statistically significant. The highest predictive accuracy (AUC: 0.947; accuracy: 56.8%) was observed in patients receiving both chemotherapy and radiation. The gradient boosting model predicted the most optimistic survival, while random forest showed a sharp decline after 15 months. Conclusions: This study emphasizes the importance of selecting appropriate analytical models for survival prediction and risk classification. Adopting these innovations, with the help of advanced machine learning and deep learning models, can enhance patient outcomes and advance precision medicine initiatives.

2 August 2024 in Mathematics
Verified
Journal Article
Open access
PDF file
ACADITYA CHAKRABORTY
ADITYA CHAKRABORTY
CTChris P. Tsokos
Chris P. Tsokos
Given the significant impact of healthcare stock changes on the global economy, including its GDP and other financial factors, we endeavored to create an analytical prediction model for forecasting the annual percentage change of these stocks. Our model, which is nonlinear, incorporates five key discoveries. We focused on predicting the average weekly closing price (pWCP) of AbbVie Inc. (North Chicago, IL, USA)’s healthcare stock (ABBV) from 1 August 2017 to 31 December 2019. The stock was chosen based on the low beta risk, high dividend yield, and high yearly percentage return criteria. Alongside predicting the weekly stock price, our model identifies the individual indicators and their interactions that notably influence the response. These indicators were ranked based on their contribution percentages to the response. The validity of the model was justified based on the root mean square error (RMSE) and R2 value by performing 10-fold cross-validation. Furthermore, an optimization process using the desirability function was implemented to determine the optimal values of the indicators that maximize the response, along with the 95% confidence and 95% prediction interval. We also visually depicted the optimal ranges of any two indicators that affect the response AWCP. In our evaluation, we compared the original and predicted responses of AWCP using our analytical model. The results demonstrated a close alignment between the two sets of observations, highlighting the high accuracy of our model. Beyond these findings, our model provides additional valuable insights into the subject area. It has undergone thorough validation and testing, confirming its high quality and the precision of our weekly stock price predictions. The information derived from the modeling and analysis is important for constructive and accurate decision-making for individual investors, portfolio managers, and financial institutions concerning the financial and economic aspects of the healthcare industry. By identifying the optimum values of the controllable contributors through the optimization process, financial institutions can make the strategic changes needed for the company’s long-term viability.

23 July 2026 in Frontiers in Public Health
Verified
Journal Article
Open access
PDF file
ACADITYA CHAKRABORTY
ADITYA CHAKRABORTY
ABA. K. M. Raquibul Bashar
A. K. M. Raquibul Bashar
Background: Asthma is one of the most prominent chronic diseases in children and one of the most challenging ailments to diagnose in infants and preschoolers in the United States. Predictive models can be instrumental in improving early diagnosis, personalized treatment strategies, and disease progression. By utilizing nationalized data, this study focuses on building and comparing high-performing analytical predictive models based on the relevant risk factors and identifying the most influential predictors. Methods: We analyzed cross-sectional BRFSS Asthma Call-Back Survey data (2011–2020; N = 9,813) and randomly split participants into training and testing sets. An XGBoost model (hyperparameters tuned via grid search) was developed and compared with SVM, random forest, LASSO, and GBM using accuracy, AUC, precision, and recall. Calibration was evaluated with reliability plots and improved using Platt scaling and isotonic regression. Predictor contributions were examined using variable-importance (VIP) and Shapley Additive Explanations (SHAP) plot. Results: Of the five predictive models, the XGBoost was found to be the best performing model with AUC: 0.95, followed by random forest (AUC: 0.9345), GBM (AUC: 0.9341), SVM (AUC 0.9304), and LASSO (AUC 0.88); however, the random forest model was found to have the highest sensitivity (0.9786), and hence preferred for initial screening of asthma. On the independent test set, calibration (10-bin reliability curves; Brier/ECE/intercept–slope) improved most with isotonic regression, specifically for Random Forest (ECE 0.0158 to 0.0086; intercept −0.174 to −0.010), whereas Platt scaling often worsened calibration, with AUC remaining largely stable across models (AUC ≈ 0.92–0.95). The top two contributing predictors were overnight hospitalization visits and time since the last asthma medication, accounting for 24.62 and 20.92%, respectively, of the asthma status, from the VIP. Conclusion: The analytical methodology of model development was found to be instrumental in the discovery of behavioral health-risk knowledge and to visualize the significance of predictive modeling from a multidimensional behavioral health survey. These insights can be instrumental in predicting different types of chronic lung diseases affecting people of all ages and can be useful for clinicians to diagnose asthma at an early stage, allowing for early intervention and proactive management.